Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for AZL30004_1

Result Summary for AZL30004_1

Result Summary

Protocol ID:	AZL30004_1
Clinical Study ID:	AZL30004 (Extension Phase)
Official Title:	A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability ofTRIZIVIR. plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ...
Phase:	Phase 3
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	Ziagen,ZIAGENAVIR
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Randomised comparison of maintenance therapy with trizivir [TZV] + efavirenz [EFV] vs TZV in naive HIV-1 infected subjects: TIME study De Wit, S.; Johnson, M.; Gazzard, B.; Bergmann, J. F.; Reynes, J.; Estrada, V.; Castagna, A., and Rockstroh, J., 7th International Congress on Drug Therapy in HIV Infection; Glasgow; Scotland. 2004 Nov 14 INDUCTION THERAPY WITH TRIZIVIR (ZIDOVUDINE/LAMIVUDINE/ABACAVIR) [TZV] PLUS EFAVIRENZ [EFV]: TIME STUDY (AZI-30004) RESULTS AT 24 WEEKS. Jean-Marie Ragnaud, Benedicte Delmas Herve Gallais Dominique Peyramond' Henri Laurichesse Pierre Dellamonica jean-Luc PL-Ilegrid ThierryAllegre NathalieAudebert' JacquesReyn onbehalfoflnfectioSud group, 6th International Congress on Drug Therapy in HIV Infection; Glasgow; Scotland. 2002 Nov 17. Johnson M., De Wit S. Gazzard B. Bergmann Jl. Reynes J. Estrada V. Castagna A. Rockstroh J. , 9th European AIDS Conference (EACS) 1st EACS Resistance and Pharmacology Workshop; Warsaw; Poland. 2003 Oct 25 Efficacy and safety of AZT/3TC/ZDV (Trizivir) maintenance treatment after first line quadruple induction therapy- interim 24 weeks: data from AZLF3004/TRISUD